A Protective and Safe Intranasal RSV Vaccine Based on a Recombinant Prefusion-Like Form of the F Protein Bound to Bacterium-Like Particles

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Rigter, Alan ^a,b   Widjaja, Ivy ^a,b   Versantvoort, Hanneke ^b   Coenjaerts, Frank E J ^c   van Roosmalen, Maarten ^b   Leenhouts, Kees ^b   Rottier, Peter J M ^a   Haijema, Bert Jan ^b   de Haan, Cornelis A M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Mucosis BV   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY AM22; ANTIBODY D25; BACTERIUM LIKE PARTICLE; FURIN; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; PALIVIZUMAB; SECRETORY IMMUNOGLOBULIN; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; IMMUNOREACTIVITY; MOUSE; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN CONFORMATION; PROTEIN MOTIF; RAT; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; GENE EXPRESSION; GENE ORDER; GENETIC VECTORS; HUMANS; LACTOCOCCUS LACTIS; LUNG; MICE; RECOMBINANT FUSION PROTEINS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SIGMODONTINAE; VACCINATION; VIRAL FUSION PROTEINS;

EID: 84881518014     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071072     Document Type: Article

References (59)

1. Collins PL, Melero JA, (2011) Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 162: 80-99.
2. Groothuis JR, Hoopes JM, Hemming VG, (2011) Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis. Adv Ther 28: 110-125.
3. Groothuis JR, Hoopes JM, Jessie VG, (2011) Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention. Adv Ther 28: 91-109.
4. Hurwitz JL, (2011) Respiratory syncytial virus vaccine development. Expert Rev Vaccines 10: 1415-1433.
5. Olmsted RA, Elango N, Prince GA, Murphy BR, Johnson PR, et al. (1986) Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc Natl Acad Sci U S A 83: 7462-7466.
6. Wertz GW, Krieger M, Ball LA, (1989) Structure and cell surface maturation of the attachment glycoprotein of human respiratory syncytial virus in a cell line deficient in O glycosylation. J Virol 63: 4767-4776.
7. Kwilas S, Liesman RM, Zhang L, Walsh E, Pickles RJ, et al. (2009) Respiratory syncytial virus grown in Vero cells contains a truncated attachment protein that alters its infectivity and dependence on glycosaminoglycans. J Virol 83: 10710-10718.
8. Hendricks DA, McIntosh K, Patterson JL, (1988) Further characterization of the soluble form of the G glycoprotein of respiratory syncytial virus. J Virol 62: 2228-2233.
9. Roberts SR, Lichtenstein D, Ball LA, Wertz GW, (1994) The membrane-associated and secreted forms of the respiratory syncytial virus attachment glycoprotein G are synthesized from alternative initiation codons. J Virol 68: 4538-4546.
10. Bukreyev A, Yang L, Fricke J, Cheng L, Ward JM, et al. (2008) The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J Virol 82: 12191-12204.
11. Lamb RA, Jardetzky TS, (2007) Structural basis of viral invasion: lessons from paramyxovirus F. Curr Opin Struct Biol. 17: 427-436.
12. Lamb RA, Paterson RG, Jardetzky TS, (2006) Paramyxovirus membrane fusion: lessons from the F and HN atomic structures. Virology 344: 30-37.
13. Tayyari F, Marchant D, Moraes TJ, Duan W, Mastrangelo P, et al. (2011) Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nat Med 17: 1132-1135.
14. Feldman SA, Audet S, Beeler JA, (2000) The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate. J Virol 74: 6442-6447.
15. Behera AK, Matsuse H, Kumar M, Kong X, Lockey RF, et al. (2001) Blocking intercellular adhesion molecule-1 on human epithelial cells decreases respiratory syncytial virus infection. Biochem Biophys Res Commun 280: 188-195.
16. Beeler JA, van Wyke Coelingh K, (1989) Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 63: 2941-2950.
17. Zimmer G, Budz L, Herrler G, (2001) Proteolytic activation of respiratory syncytial virus fusion protein. Cleavage at two furin consensus sequences. J Biol Chem 276: 31642-31650.
18. Gonzalez-Reyes L, Ruiz-Arguello MB, Garcia-Barreno B, Calder L, Lopez JA, et al. (2001) Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion. Proc Natl Acad Sci U S A 98: 9859-9864.
19. McLellan JS, Yang Y, Graham BS, Kwong PD, (2011) Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol 85: 7788-7796.
20. Swanson KA, Settembre EC, Shaw CA, Dey AK, Rappuoli R, et al. (2011) Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A 108: 9619-9624.
21. van Roosmalen ML, Kanninga R, El Khattabi M, Neef J, Audouy S, et al. (2006) Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria. Methods 38: 144-149.
22. Ramirez K, Ditamo Y, Rodriguez L, Picking WL, van Roosmalen ML, et al. (2010) Neonatal mucosal immunization with a non-living, non-genetically modified Lactococcus lactis vaccine carrier induces systemic and local Th1-type immunity and protects against lethal bacterial infection. Mucosal Immunol 3: 159-171.
23. Saluja V, Amorij JP, van Roosmalen ML, Leenhouts K, Huckriede A, et al. (2010) Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant. AAPS J 12: 109-116.
24. de Haan A, Haijema BJ, Voorn P, Meijerhof T, van Roosmalen ML, et al. (2012) Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration. Vaccine 30: 4884-4891.
25. Audouy SA, van Roosmalen ML, Neef J, Kanninga R, Post E, et al. (2006) Lactococcus lactis GEM particles displaying pneumococcal antigens induce local and systemic immune responses following intranasal immunization. Vaccine 24: 5434-5441.
26. Audouy SA, van Selm S, van Roosmalen ML, Post E, Kanninga R, et al. (2007) Development of lactococcal GEM-based pneumococcal vaccines. Vaccine 25: 2497-2506.
27. Ramasamy R, Yasawardena S, Zomer A, Venema G, Kok J, et al. (2006) Immunogenicity of a malaria parasite antigen displayed by Lactococcus lactis in oral immunisations. Vaccine 24: 3900-3908.
28. Nganou-Makamdop K, van Roosmalen ML, Audouy SA, van Gemert GJ, Leenhouts K, et al. (2012) Bacterium-like particles as multi-epitope delivery platform for Plasmodium berghei circumsporozoite protein induce complete protection against malaria in mice. Malar J 11: 50.
29. Magro M, Mas V, Chappell K, Vazquez M, Cano O, et al. (2012) Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci U S A 109: 3089-3094.
30. Tan L, Lemey P, Houspie L, M CV, Jansen NJ, et al. (2012) Genetic Variability among Complete Human Respiratory Syncytial Virus Subgroup A Genomes: Bridging Molecular Evolutionary Dynamics and Epidemiology. PLoS One 7: e51439.
31. Zeng Q, Langereis MA, van Vliet AL, Huizinga EG, de Groot RJ, (2008) Structure of coronavirus hemagglutinin-esterase offers insight into corona and influenza virus evolution. Proc Natl Acad Sci U S A 105: 9065-9069.
32. de Vries RP, de Vries E, Bosch BJ, de Groot RJ, Rottier PJ, et al. (2010) The influenza A virus hemagglutinin glycosylation state affects receptor-binding specificity. Virology 403: 17-25.
33. Harbury PB, Zhang T, Kim PS, Alber T, (1993) A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants. Science 262: 1401-1407.
34. Kwakkenbos MJ, Diehl SA, Yasuda E, Bakker AQ, van Geelen CM, et al. (2010) Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat Med 16: 123-128.
35. Beaumont T, Bakker AQ, Yasuda E (2012) RSV specific binding molecule. Unites States Patent Application Publication US/2012/0070446 A1.
36. Prince GA, Curtis SJ, Yim KC, Porter DD, (2001) Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol 82: 2881-2888.
37. Ruiz-Arguello MB, Gonzalez-Reyes L, Calder LJ, Palomo C, Martin D, et al. (2002) Effect of proteolytic processing at two distinct sites on shape and aggregation of an anchorless fusion protein of human respiratory syncytial virus and fate of the intervening segment. Virology 298: 317-326.
38. Ruiz-Arguello MB, Martin D, Wharton SA, Calder LJ, Martin SR, et al. (2004) Thermostability of the human respiratory syncytial virus fusion protein before and after activation: implications for the membrane-fusion mechanism. J Gen Virol 85: 3677-3687.
39. Chaiwatpongsakorn S, Epand RF, Collins PL, Epand RM, Peeples ME, (2011) Soluble respiratory syncytial virus fusion protein in the fully cleaved, pretriggered state is triggered by exposure to low-molarity buffer. J Virol 85: 3968-3977.
40. Yin HS, Wen X, Paterson RG, Lamb RA, Jardetzky TS, (2006) Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature 439: 38-44.
41. Yang X, Farzan M, Wyatt R, Sodroski J, (2000) Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins. J Virol 74: 5716-5725.
42. Wei CJ, Xu L, Kong WP, Shi W, Canis K, et al. (2008) Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J Virol 82: 6200-6208.
43. Cornelissen LA, de Vries RP, de Boer-Luijtze EA, Rigter A, Rottier PJ, et al. (2010) A single immunization with soluble recombinant trimeric hemagglutinin protects chickens against highly pathogenic avian influenza virus H5N1. PLoS One 5: e10645.
44. de Vries RP, de Vries E, Moore KS, Rigter A, Rottier PJ, et al. (2011) Only two residues are responsible for the dramatic difference in receptor binding between swine and new pandemic H1 hemagglutinin. J Biol Chem 286: 5868-5875.
45. Magro M, Andreu D, Gomez-Puertas P, Melero JA, Palomo C, (2010) Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein. J Virol 84: 7970-7982.
46. McLellan JS, Chen M, Leung S, Graepel KW, Du X, et al. (2013) Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody. Science.
47. Connors M, Kulkarni AB, Firestone CY, Holmes KL, Morse HC, (1992) Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells. J Virol 66: 7444-7451.
48. Graham BS, Henderson GS, Tang YW, Lu X, Neuzil KM, et al. (1993) Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol 151: 2032-2040.
49. Waris ME, Tsou C, Erdman DD, Zaki SR, Anderson LJ, (1996) Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol 70: 2852-2860.
50. Murphy BR, Sotnikov AV, Lawrence LA, Banks SM, Prince GA, (1990) Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 8: 497-502.
51. Prince GA, Jenson AB, Hemming VG, Murphy BR, Walsh EE, et al. (1986) Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus. J Virol 57: 721-728.
52. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, et al. (2010) Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375: 1545-1555.
53. Widmer K, Zhu Y, Williams JV, Griffin MR, Edwards KM, et al. (2012) Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults. J Infect Dis 206: 56-62.
54. Connolly SA, Leser GP, Yin HS, Jardetzky TS, Lamb RA, (2006) Refolding of a paramyxovirus F protein from prefusion to postfusion conformations observed by liposome binding and electron microscopy. Proc Natl Acad Sci U S A 103: 17903-17908.
55. Yin HS, Paterson RG, Wen X, Lamb RA, Jardetzky TS, (2005) Structure of the uncleaved ectodomain of the paramyxovirus (hPIV3) fusion protein. Proc Natl Acad Sci U S A 102: 9288-9293.
56. The IMpact-RSV Study Group (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102: 531-537.
57. Weltzin R, Traina-Dorge V, Soike K, Zhang JY, Mack P, et al. (1996) Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection. J Infect Dis 174: 256-261.
58. Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, et al. (2009) Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 15: 34-41.
59. Graham BS, (2011) Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 239: 149-166.